The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
Open accessAbstract
We aimed to establish an objective point score to guide the decision for retreatment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). In all, 222 patients diagnosed with HCC and treated with multiple TACE cycles between January 1999 and December 2009 at the Departments of Gastroenterology/Hepatology of the Medical Universities of Vienna (training cohort) and Innsbruck (validation cohort) were included. We investigated the effect of the first TACE on parameters of liver function and tumor response and their impact on overall survival (OS, log rank test) and developed a point score (ART score: Assessment for Retreatment with TACE) in the training cohort (n = 107, Vienna) by using a stepwise Cox regression model. The ART score was externally validated in an independent validation cohort (n = 115, Innsbruck). The increase of aspartate aminotransferase (AST) by >25% (hazard ratio [HR] 8.4; P < 0.001), an increase of Child-Pugh score of 1 (HR 2.0) or ≥2 points (HR 4.4) ( P < 0.001) from baseline, and the absence of radiologic tumor response (HR 1.7; P = 0.026) remained independent negative prognostic factors for OS and were used to create the ART score. The ART score differentiated two groups (0-1.5 points; ≥2.5 points) with distinct prognosis (median OS: 23.7 versus 6.6 months; P < 0.001) and a higher ART score was associated with major adverse events after the second TACE ( P = 0.011). These results were confirmed in the external validation cohort and remained significant irrespective of Child-Pugh stage and the presence of ascites prior the second TACE. Conclusion: An ART score of ≥2.5 prior the second TACE identifies patients with a dismal prognosis who may not profit from further TACE sessions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Surgery and portal hypertension.
Child, C. G., & Turcotte, J. (1964) · PubMed · Cited by 1,933
Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,481
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
Forner, A., Reig, M. E., Rodriguez de Lope, C., & Bruix, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247133 · Cited by 1,110
Raoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Graziadei, I. W., Sandmueller, H., Waldenberger, P., Koenigsrainer, A., Nachbaur, K., Jaschke, W., Margreiter, R., & Vogel, W. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50106 · Cited by 439
Self-citationGillmore, R., Stuart, S., Kirkwood, A., Hameeduddin, A., Woodward, N., Burroughs, A. K., & Meyer, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.007 · Cited by 324
Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions
Heinzl, H., & Kaider, A. (1997) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(97)00043-6 · Cited by 283
Self-citationShim, J. H., Lee, H. C., Kim, S.-O., Shin, Y. M., Kim, K. M., Lim, Y.-S., & Suh, D. J. (2012) · Radiology · doi:10.1148/radiol.11110282 · Cited by 251
Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
Pinter, M., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Stauber, R., Grünberger, B., Müller, C., Kölblinger, C., et al. (2012) · Radiology · doi:10.1148/radiol.12111550 · Cited by 197
Self-citationSieghart, W., Pinter, M., Hucke, F., Graziadei, I. W., Schöniger–Hekele, M., Müller, C., Vogel, W., Trauner, M., & Peck‐Radosavljevic, M. (2012) · Hepatology · doi:10.1002/hep.26057 · Cited by 134
Self-citationRaoul, J., Bruix, J., Greten, T. F., Sherman, M., Mazzaferro, V., Hilgard, P. A., Scherübl, H., Scheulen, M. E., Germanidis, G. S., Dominguez, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.009 · Cited by 123
Memon, K., Kulik, L., Lewandowski, R. J., Wang, E., Ryu, R. K., Riaz, A., Nikolaidis, P., Miller, F. H., Yaghmai, V., Baker, T., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.020 · Cited by 95
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
Pinter, M., Sieghart, W., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Weißmann, A.-C., Kornek, G. V., Matejka, J., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04823.x · Cited by 73
Self-citationHucke, F., Sieghart, W., Schöniger–Hekele, M., Peck‐Radosavljevic, M., & Müller, C. (2011) · Wiener klinische Wochenschrift · doi:10.1007/s00508-011-0033-9 · Cited by 53
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[305] 308] Response evaluation criteria in solid tumors (RECIST) v1.”
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Metadata
- Authors
- Sieghart, W., Hucke, F., Pinter, M., Graziadei, I., Vogel, W., Müller, C., Heinzl, H., Trauner, M., & Peck-Radosavljevic, M.
- Venue
- Hepatology
- Published
- 2013-06
- Volume
- 57
- Issue
- 6
- Pages
- 2261-2273
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2061291622
- Cited by
- 343
- References
- 22
- FWCI
- 16.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.